Dear Stakeholders,
I want to take a moment to update you on our progress with the development of Ocumetics’ accommodative intraocular lens (AIOL), which will soon undergo its first-in-human (FIH) trials.
As you know, we are committed to pioneering advanced ophthalmic technologies that will transform the way we treat cataracts and other vision conditions. In recent internal testing of our AIOL, we identified an opportunity to make key design improvements that will enhance both its performance and safety profile. These important improvements do not require significant costs or delays, but they do require adjustments to our current manufacturing process.
To implement these changes, we will need to reorder raw materials, create new lens moulds, and conduct additional internal testing to ensure the lens meets the highest safety, efficacy, and regulatory standards. As a result, we are adjusting our timeline for the first-in-human surgeries. We now anticipate that the FIH trials will begin approximately 6-8 weeks from our previously published date.
I want to emphasize that this decision, though it results in a delay, reflects our unwavering commitment to delivering a product that meets the highest possible standards. Moving a product from concept to human trials is a rigorous process, and it is essential that we maintain the highest level of quality and safety at every stage. These enhancements to the AIOL will improve its overall performance and ensure that we are providing the best possible solution for those impacted by cataracts and other vision challenges.
I am confident that this improvement will result in a more effective, safe, and reliable lens that will set new benchmarks in the ophthalmic industry.
Thank you for your continued support as we strive to bring this transformative technology to market.
Best Regards,
Dean Burns
President & CEO
Ocumetics Technology Corp.
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million Dear Ocumetics Investors, I am thrilled to share some exciting news that marks a significant milestone for our company and our mission to revolutionize eye care technology. I am pleased to announce that Ocumetics has successfully closed the first
Understanding the significance of the biocompatibility journey and why it’s essential for US FDA Approval Earlier this week, Ocumetics sent out a press release announcing that we completed our three-month biocompatibility study and received very favorable results. Receiving favorable results in this study is a critical aspect in the field of health care and medical
Tired of glasses? New lens technologies might offer a better way to see and experience the world. Anyone who relies on corrective eyewear has experienced its drawbacks. Maybe you are approaching your 50’s and need glasses to see up close. Maybe you left your reading glasses at home and find yourself asking for help deciphering
Ocumetics believes its accommodating lens technology could transform the eye care industry. Dr. Garth Webb, Ocumetics’ Founder and Chief Scientific Officer, thinks nothing is as beautiful as the lens in the human eye. “It’s this gorgeous, crystal-like orb that hides just behind the pupil,” he says. But it doesn’t stay that way forever. Inevitably, as
